Comparison · NCT01313182-4bd46373
3M Skin and Nasal Antiseptic vs Bactroban Nasal: Measure Rate of Staphylococcus Aureus Resistance to Mupirocin.
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. 3M Skin and Nasal Antiseptic vs Bactroban Nasal: Measure Rate of Staphylococcus Aureus Resistance to Mupirocin. Trial comparisons, record NCT01313182-4bd46373. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01313182-4bd46373
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0249 | 0.0164 | 0.0378 | wilson | |
| Risk in group 2 | 0.0281 | 0.0189 | 0.0414 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00313 | -0.019 | 0.0127 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.889 | 0.499 | 1.58 | log | |
| Odds ratio, group 1 over group 2 | 0.886 | 0.489 | 1.6 | log | |
| Number needed to treat, for one fewer participant with the outcome on 3M Skin and Nasal Antiseptic than on Bactroban Nasal | 320 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | 3M Skin and Nasal Antiseptic | Povidone-iodine solution 5% w/w (0.5% available iodine) USP Patient Preoperative Skin Preparation~Povidone-iodine solution 5% w/w (0.5% available iodine) Patient Preoperative Skin Preparation: The solution is applied to for 30 seconds to each nostril twice for a total of 2 minutes. The solution is applied by rotating the applicator around the circumference of the nostril for 15 seconds and then rotating the applicator in the anterior nares for 15 seconds. | 21 | 842 | OG000 |
| Group 2 | Bactroban Nasal | Mupirocin calcium ointment, 2%~mupirocin calcium ointment, 2%: Approximately one-half of the ointment from the single-use tube should be applied into 1 nostril and the other half into the other nostril twice daily (morning and evening) for 5 days.~After application, the nostrils should be closed by pressing together and releasing the sides of the nose repetitively for approximately 1 minute. This will spread the ointment throughout the nares. | 24 | 855 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Measure Rate of Staphylococcus Aureus Resistance to Mupirocin.
- Description
- Lab cultured isolates - they will measure rate of Staphylococcus aureus resistance to mupirocin. Both arms were sampled and tested post-op.
- Time frame
- Isolates collected and frozen immediately post-surgery.
- Population
Source ClinicalTrials.gov
Trial
- Title
- Prevention of Surgical Site Infections: Effectiveness of Nasal Povidone-Iodine and Nasal Mupirocin
- NCT number
- NCT01313182
- Phases
- PHASE4
- Conditions
- Surgical Site Infection
- Interventions
- mupirocin calcium ointment, 2%, 3M Skin and Nasal Antiseptic
- Lead sponsor
- Solventum US LLC
- Results first posted
- 2014-05-19
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01313182?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01313182-4bd46373